ImmunoScape is at the forefront of developing innovative T cell receptor (TCR)-based therapeutics specifically targeting solid tumors. The company employs its proprietary Deep Immunomics platform, which facilitates the rapid identification of tumor-specific TCRs by analyzing millions of T cells from blood and tissue samples. This platform generates high-dimensional profiles that help in selecting TCRs with the potential for safe and effective therapeutic applications. Additionally, ImmunoScape utilizes its TargetScape® technology, a high-throughput screening method that allows for the detailed profiling of tumor antigen-reactive T cells at a single-cell level, thereby enhancing the discovery of TCRs that can be used in clinical settings.

Furthermore, ImmunoScape's Machine Learning platform, known as TCAPS, integrates comprehensive data on TCR sequences, gene expression, and surface marker profiles to predict T cell specificity in an antigen-independent manner. This capability accelerates the identification of novel TCR candidates, streamlining the development of next-generation TCR-based therapies. The company is building a diverse pipeline of autologous cell therapy programs that target a wide range of solid tumors, leveraging a library of prevalent HLA alleles to ensure broad applicability across different populations. Through these advanced technologies, ImmunoScape aims to deliver effective and differentiated treatments for cancer patients.

United States

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.

To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.


ImmunoScape

Company Details